Science & Enterprise subscription

Follow us on Twitter

  • As mobile phones, smart watches, and tablets play an increasingly key role in our daily lives, a new report shows m…
    about 2 days ago
  • New post on Science and Enterprise: Infographic – Mobile Industry’s Economic Role #Science #Business
    about 2 days ago
  • FDA expert panel gives thumbs-up to Aimmune’s peanut allergy drug
    about 2 days ago
  • A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million i…
    about 2 days ago
  • New post on Science and Enterprise: Migraine Drug Developer Raises $82.5M in IPO #Science #Business
    about 2 days ago

Please share Science & Enterprise

Third Rock Closes $516M Health Care Venture Fund

Currency dice (MD4 Group/Flickr)Third Rock Ventures in Boston and San Francisco raised $516 million for its Fund III to invest in new health care enterprises. Wth the fund, the company plans to support up to 16 health and medicine start-ups.

Third Rock aims to finance new companies offering products or services in health care with high potential impact. Investments include start-ups working in personalized medicine, epigenetics, cancer metabolism, obesity, and rare genetic disorders.  The company also finances new enterprises in cardiovascular disease, ophthalmology, pain and central nervous system disorders, and molecular diagnostics.

The company says that since its founding in 2007, its investments totaling some $1.3 billion resulted in launching 31 health care companies now in its portfolio. Its approach includes both financing and management support, with initial investments of about $50 million backing business ideas from academia, entrepreneurs, and industry spin-offs.

Third Rock says it encourages its portfolio companies to form collaborations to advance their businesses. Last week, Blueprint Medicines — a Third Rock portfolio company specializing in genomics and personalized therapies — formed a partnership with Massachusetts General Hospital and Wellcome Trust Sanger Institute to identify new cancer targets.

Two of Third Rock’s portfolio companies so far were acquird by larger enterprises: Alnara Pharmaceuticals by Eli Lilly and Company in 2010, and Lotus Tissue Repair by Shire plc in 2013.

Read more:

Hat tip: Fierce Biotech

Image: MD4 Group/Flickr

*     *     *

Please share Science & Enterprise ...

Comments are closed.